COSMO Pharmaceuticals SA risk profile
56 Elevated one input has moved against it
Measured 1 September 2026 from 0RGI's filed statements. Recomputed nightly.
56 (Elevated), driven by Cash conversion at 100, over 5 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 71 | Stretched | Volatile | Drawdown from the 52-week high — 54.8% |
| Operating pressure | 81 | Acute | Worsening | Costs outgrowing revenue — +54.7 percentage points |
| Cash conversion | 100 | Acute | Worsening | Capital spending against operating cash — -0.44x |
| Leverage and coverage | 0 | Contained | Stable | Net debt to EBITDA — -4.32x |
| Competitive position | 47 | Elevated | Stable | Revenue-growth gap against peers — -24.3 percentage points |
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 17Johnson & Johnson 37Abbvie Inc 46Roche Holding AG 32Merck & Co Inc 26Novartis AG 25Astrazeneca plc 30AMGEN Inc 33Thermo Fisher Scientific Inc 45Novo Nordisk A/S 23Abbott Laboratories 43Gilead Sciences Inc 31
Financials, valuation and price history for COSMO Pharmaceuticals SA